Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 3Stomach Neoplasms 2Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Liver Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 685130-nm albumin-bound paclitaxel 199Fluorouracil 190Oxaliplatin 177Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 133Irinotecan 114Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 73Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 51Cyclophosphamide 50folfirinox 45Specimen Handling 43Docetaxel 42Cetuximab 40Biopsy 39irinotecan sucrosofate 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Hydroxyurea × Gastrointestinal × Clear all
NCT00019474 2018-09-14

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

Montefiore Medical Center

Phase 2 Completed
60 enrolled
Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡